Examkin

Soru

Zorluk: ZorMonitoring and Treatment Evaluation

A 6565-year-old man with symptomatic heart failure with reduced ejection fraction (LVEF 30%30\%) is evaluated in the clinic. He is currently taking lisinopril, metoprolol succinate, and spironolactone. His blood pressure is 118/75118/75 mmHg, and his heart rate is 6868/min. A basic metabolic panel shows a serum potassium of 4.64.6 mEq/L and a serum creatinine of 1.21.2 mg/dL. To further optimize his guideline-directed medical therapy, the physician decides to replace lisinopril with sacubitril-valsartan.

Which of the following are required steps in the execution and monitoring of this treatment transition? (Select all that apply)

  1. Enforce a 3636-hour washout period after the final dose of lisinopril before administering the first dose of sacubitril-valsartanCevap
  2. Reassess serum potassium and renal function with a basic metabolic panel 11 to 22 weeks after initiating sacubitril-valsartanCevap
  3. C
    Discontinue spironolactone prior to the transition to avoid severe, life-threatening hyperkalemia
  4. D
    Utilize serial measurements of serum B-type natriuretic peptide (BNP) to evaluate long-term therapeutic efficacy and volume status
  5. E
    Temporarily withhold metoprolol succinate for 4848 hours during the transition to mitigate the risk of profound synergistic bradycardia

Cevap

The required steps are enforcing a 36-hour washout period after the final lisinopril dose before starting sacubitril-valsartan, and reassessing serum potassium and renal function 1 to 2 weeks after initiation.
Sacubitril-valsartan is an angiotensin receptor-neprilysin inhibitor (ARNI) that improves morbidity and mortality in heart failure with reduced ejection fraction (HFrEF). Neprilysin normally degrades vasoactive peptides, including bradykinin. Because ACE inhibitors (like lisinopril) also inhibit bradykinin breakdown, the concurrent use of an ACE inhibitor and an ARNI significantly increases the risk of life-threatening angioedema. Therefore, a strict 3636-hour washout period is mandatory when transitioning from an ACE inhibitor to an ARNI. (Note: this washout is not required when transitioning from an ARB to an ARNI). Additionally, ARNIs can cause renal impairment and hyperkalemia. Because this patient is concurrently taking spironolactone (a potassium-sparing mineralocorticoid receptor antagonist), reassessing serum creatinine and potassium 11 to 22 weeks after initiation is a necessary monitoring step to prevent severe hyperkalemia or acute kidney injury.

Adım Adım Çözüm

1
Analyze the patient's current medication regimen and the planned transition.
The patient is transitioning from an angiotensin-converting enzyme (ACE) inhibitor (lisinopril) to an angiotensin receptor-neprilysin inhibitor (ARNI, sacubitril-valsartan).
Identifying the specific drug classes is essential for determining washout protocols and necessary monitoring.
2
Determine the washout requirements between an ACE inhibitor and an ARNI.
A strict 36-hour washout period is required.
Both ACE inhibitors and neprilysin inhibitors prevent the breakdown of bradykinin. Overlapping these medications drastically increases the risk of life-threatening angioedema.
3
Identify necessary laboratory monitoring based on the new regimen and concurrent medications.
A basic metabolic panel must be checked in 1 to 2 weeks.
ARNIs can decrease renal perfusion and increase potassium retention. This risk is compounded by the patient's concurrent use of spironolactone (a potassium-sparing diuretic).
4
Evaluate the distractors regarding biomarker monitoring and concurrent therapies.
BNP cannot be used for monitoring, and concurrent GDMT (spironolactone and metoprolol) must be continued.
Neprilysin degrades BNP, so sacubitril falsely elevates BNP levels (NT-proBNP should be used instead). Furthermore, stopping beta-blockers or MRAs inappropriately removes established mortality benefits.

Anahtar Kavram

Monitoring and transitioning protocols for Angiotensin Receptor-Neprilysin Inhibitors (ARNIs) in Heart Failure
Tahmini Süre:2m 0s
Bu soruyu puanla

Konular

Monitoring and Treatment Evaluation

Bu konudan daha fazla soru